Polycystic Ovary Syndrome (PCOS) Renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to Reflect Metabolic Risks

Experts have announced the renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) at the 28th European Congress of Endocrinology in May 2026, with the change published in The Lancet. This renaming acknowledges that the condition, affecting one in 10 women, has significant health risks extending beyond the female reproductive system, including insulin resistance, which has often been under-recognized.